Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price increased by Wells Fargo & Company from $275.00 to $287.00 in a research note released on Friday morning,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the company. Bank of America raised their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Sanford C. Bernstein decreased their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Finally, Chardan Capital reissued a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $310.22.

Alnylam Pharmaceuticals Stock Up 11.8 %

Shares of Alnylam Pharmaceuticals stock opened at $283.34 on Friday. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company’s 50 day moving average is $257.16 and its 200 day moving average is $259.74. The company has a market cap of $36.68 billion, a price-to-earnings ratio of -130.57 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares of the company’s stock, valued at $8,366,003.62. The trade was a 2.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,234 shares of company stock worth $19,958,097. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Jennison Associates LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $61,160,000. Strategic Financial Concepts LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $41,529,000. Truist Financial Corp raised its position in Alnylam Pharmaceuticals by 136.6% during the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock valued at $1,035,000 after purchasing an additional 2,539 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after purchasing an additional 8,462 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Alnylam Pharmaceuticals by 13.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock worth $4,687,000 after purchasing an additional 2,285 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.